Olanib 50 mg Capsule

Generic Name: Olaparib
Brand Name: Olanib
Strength: 50 mg
Form: Capsules
Pack Size: Varies (commonly 112 capsules per box)
Manufacturer: Everest Pharmaceuticals
Distributed by: NP Molecule

Indications:

Olanib (Olaparib) is indicated for the treatment of:

• Maintenance treatment of adult patients with BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

• Germline BRCA-mutated HER2-negative metastatic breast cancer.

• BRCA-mutated metastatic pancreatic cancer (in combination with chemotherapy).

• Prostate cancer in certain genetic contexts.

Pharmacology:

Olaparib is a potent PARP (Poly ADP-ribose polymerase) inhibitor, which prevents cancer cells from repairing damaged DNA. This leads to cancer cell death, particularly in tumors with defective BRCA1/BRCA2 or homologous recombination repair (HRR) genes.

Dosage & Administration:

• Standard dosing is 300 mg twice daily, but the 50 mg capsule allows for flexible dosing based on patient-specific needs.

• Administer orally with or without food.

• Capsules must be swallowed whole—do not chew, crush, or split.

Drug Interactions:

• Caution with CYP3A inhibitors or inducers (e.g., ketoconazole, rifampin).

• Avoid co-administration with drugs that lower the seizure threshold.

Contraindications:

• Hypersensitivity to Olaparib or any of its components.

• Use with caution in patients with liver or kidney impairment.

Side Effects:

• Common: Nausea, fatigue, anemia, vomiting, diarrhea.

• Serious: Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), pneumonitis (rare).

Pregnancy & Lactation:

• Contraindicated during pregnancy due to fetal harm risk.

• Breastfeeding should be avoided during and for at least 1 month after treatment.

Precautions & Warnings:

• Monitor blood counts regularly.

• Discontinue if signs of MDS/AML appear.

• Dose modifications may be required for adverse effects or organ impairment.

Overdose Effects:

• Can lead to intensified side effects, especially hematological toxicities.

• Provide symptomatic and supportive care.

Therapeutic Class:

• PARP Inhibitor

• Targeted Anti-Cancer Therapy

Storage Conditions:

• Store below 30°C in a dry place.

• Protect from moisture and direct light.

• Keep out of reach of children.